Yang L, Ma A. Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. FBEM [Internet]. 2023 Apr. 25 [cited 2026 Jul. 16];8(3):178-84. Available from: https://drpress.org/ojs/index.php/fbem/article/view/7835